1. Home
  2. CELC vs EMPD Comparison

CELC vs EMPD Comparison

Compare CELC & EMPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • EMPD
  • Stock Information
  • Founded
  • CELC 2011
  • EMPD 2020
  • Country
  • CELC United States
  • EMPD United States
  • Employees
  • CELC N/A
  • EMPD N/A
  • Industry
  • CELC Medical Specialities
  • EMPD
  • Sector
  • CELC Health Care
  • EMPD
  • Exchange
  • CELC Nasdaq
  • EMPD Nasdaq
  • Market Cap
  • CELC 440.0M
  • EMPD 428.3M
  • IPO Year
  • CELC 2017
  • EMPD 2021
  • Fundamental
  • Price
  • CELC $55.07
  • EMPD $7.31
  • Analyst Decision
  • CELC Strong Buy
  • EMPD
  • Analyst Count
  • CELC 5
  • EMPD 0
  • Target Price
  • CELC $53.60
  • EMPD N/A
  • AVG Volume (30 Days)
  • CELC 862.3K
  • EMPD 915.8K
  • Earning Date
  • CELC 11-13-2025
  • EMPD 11-11-2025
  • Dividend Yield
  • CELC N/A
  • EMPD N/A
  • EPS Growth
  • CELC N/A
  • EMPD N/A
  • EPS
  • CELC N/A
  • EMPD N/A
  • Revenue
  • CELC N/A
  • EMPD $3,501,765.00
  • Revenue This Year
  • CELC N/A
  • EMPD N/A
  • Revenue Next Year
  • CELC N/A
  • EMPD N/A
  • P/E Ratio
  • CELC N/A
  • EMPD N/A
  • Revenue Growth
  • CELC N/A
  • EMPD N/A
  • 52 Week Low
  • CELC $7.58
  • EMPD $6.50
  • 52 Week High
  • CELC $63.06
  • EMPD $11.37
  • Technical
  • Relative Strength Index (RSI)
  • CELC 59.21
  • EMPD N/A
  • Support Level
  • CELC $50.44
  • EMPD N/A
  • Resistance Level
  • CELC $63.06
  • EMPD N/A
  • Average True Range (ATR)
  • CELC 3.03
  • EMPD 0.00
  • MACD
  • CELC -0.90
  • EMPD 0.00
  • Stochastic Oscillator
  • CELC 44.24
  • EMPD 0.00

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About EMPD Empery Digital Inc. Common stock

Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.

Share on Social Networks: